Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2013

01-01-2013 | Letter to the Editor

Outcome of discontinuing bevacizumab prior to malignant glioma progression

Authors: Wendy J. Sherman, Jeffrey J. Raizer, Sean A. Grimm

Published in: Journal of Neuro-Oncology | Issue 1/2013

Login to get access

Excerpt

Bevacizumab (Avastin®, Genentech Inc., San Francisco, CA) was granted accelerated approval from the Food and Drug Administration as single agent treatment of recurrent glioblastoma (GB) based on the high radiologic response rate demonstrated in two phase 2 clinical trials. …
Literature
1.
2.
Verhoeff JJ, van Tellingen O, Claes A et al (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444PubMedCrossRef
3.
Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787PubMedCrossRef
Metadata
Title
Outcome of discontinuing bevacizumab prior to malignant glioma progression
Authors
Wendy J. Sherman
Jeffrey J. Raizer
Sean A. Grimm
Publication date
01-01-2013
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-012-0985-2

Other articles of this Issue 1/2013

Journal of Neuro-Oncology 1/2013 Go to the issue

Clinical Study

Post-treatment T1 shortening in primary CNS lymphoma

Clinical Study

MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas

Laboratory Investigation

The role of LAT1 in 18F-DOPA uptake in malignant gliomas

Clinical Study

Continuous daily sunitinib for recurrent glioblastoma

Clinical Study

Epilepsy in the end-of-life phase in patients with high-grade gliomas

Clinical Study

Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma